Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Warren Olanow

Showing results (81-90 of 189) with videos related to

Pageof 19
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|August 7, 2021
On-Demand Therapy for OFF Episodes in Parkinson's DiseaseC Warren Olanow, Werner Poewe, Olivier Rascol, et al.
Archives of Neurology|June 16, 2005
Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic studyFabrizio Stocchi, Laura Vacca, Stefano Ruggieri, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 22, 2014
Peripheral alpha-synuclein and Parkinson's diseaseC Warren Olanow, Dustin R Wakeman, Jeffrey H Kordower
Movement Disorders : Official Journal of the Movement Disorder Society|October 7, 2020
A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another PandemicKarl Kieburtz, Russell Katz, Andrew McGarry, et al.
The Biochemical Journal|April 10, 2003
Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell linesVenugopalan D Nair, C Warren Olanow, Stuart C Sealfon
Annals of Neurology|April 1, 2003
Neuroprotection for Parkinson's disease: prospects and promisesC Warren Olanow, Anthony H V Schapira, Yves Agid
Annals of Neurology|January 8, 2009
Why have we failed to achieve neuroprotection in Parkinson's disease?C Warren Olanow, Karl Kieburtz, Anthony H V Schapira
The Journal of Pharmacology and Experimental Therapeutics|January 23, 2003
Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stressCatherine Mytilineou, Ruth H Walker, Ruth JnoBaptiste, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 2, 2018
Adverse event reporting in clinical trials in Parkinson's Disease: Time for changeC Warren Olanow, Christopher Kenney, Stephen Bandak, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 5, 2003
Sleepiness in Parkinson's disease: a controlled studyMatthew A Brodsky, James Godbold, Tom Roth, et al.
Pageof 19

Showing results (81-90 of 189) with videos related to

Sort By:
Pageof 19
Movement Disorders : Official Journal of the Movement Disorder Society|August 7, 2021
On-Demand Therapy for OFF Episodes in Parkinson's DiseaseC Warren Olanow, Werner Poewe, Olivier Rascol, et al.
Archives of Neurology|June 16, 2005
Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic studyFabrizio Stocchi, Laura Vacca, Stefano Ruggieri, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 22, 2014
Peripheral alpha-synuclein and Parkinson's diseaseC Warren Olanow, Dustin R Wakeman, Jeffrey H Kordower
Movement Disorders : Official Journal of the Movement Disorder Society|October 7, 2020
A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another PandemicKarl Kieburtz, Russell Katz, Andrew McGarry, et al.
The Biochemical Journal|April 10, 2003
Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell linesVenugopalan D Nair, C Warren Olanow, Stuart C Sealfon
Annals of Neurology|April 1, 2003
Neuroprotection for Parkinson's disease: prospects and promisesC Warren Olanow, Anthony H V Schapira, Yves Agid
Annals of Neurology|January 8, 2009
Why have we failed to achieve neuroprotection in Parkinson's disease?C Warren Olanow, Karl Kieburtz, Anthony H V Schapira
The Journal of Pharmacology and Experimental Therapeutics|January 23, 2003
Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stressCatherine Mytilineou, Ruth H Walker, Ruth JnoBaptiste, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 2, 2018
Adverse event reporting in clinical trials in Parkinson's Disease: Time for changeC Warren Olanow, Christopher Kenney, Stephen Bandak, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 5, 2003
Sleepiness in Parkinson's disease: a controlled studyMatthew A Brodsky, James Godbold, Tom Roth, et al.
Pageof 19